Skip to main content
. 2018 Jul 12;13(7):e0200474. doi: 10.1371/journal.pone.0200474

Fig 2. AZM therapy reduces cardiac inflammatory monocytes after MI.

Fig 2

Representative FACS plots demonstrating the gating strategy for Ly6Chi (CD45+/CD115hi/Ly6-Chi) and Ly6Clo (CD45+/CD115hi/Ly6-Clo) monocytes (Panel A). Quantitative analyses of monocyte subpopulations in PB and heart tissue demonstrating no significant changes in PB monocyte subpopulations but significant reduction in cardiac Ly6Chi population throughout the different time points after MI in AZM treated mice (Panel B) (n = 4 MI and 3 sham mice/group/time point, *P<0.05 and **P<0.01 compared to vehicle controls). Data presented as mean ± SEM. AZM, azithromycin; PB, peripheral blood.